14/120
0.6 / 5 stars
All 120 Win/Lose results shown below
ATNM Roast Me summary
Actinium Pharmaceuticals, Inc. (ATNM). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseATNM / S&P -1.51% / 15.20% |
LoseATNM / S&P ATNM unavailable / 15.00% |
LoseATNM / S&P ATNM unavailable / 50.40% |
| 2026-Q10/3 |
LoseATNM / S&P -26.84% / -4.33% |
LoseATNM / S&P ATNM unavailable / 11.30% |
LoseATNM / S&P ATNM unavailable / 27.70% |
| 2025-Q40/3 |
LoseATNM / S&P -15.00% / 2.65% |
LoseATNM / S&P ATNM unavailable / 9.00% |
LoseATNM / S&P ATNM unavailable / 13.40% |
| 2025-Q31/3 |
WinATNM / S&P 14.29% / 8.12% |
LoseATNM / S&P ATNM unavailable / 4.61% |
LoseATNM / S&P ATNM unavailable / 13.45% |
| 2025-Q20/3 |
LoseATNM / S&P -13.04% / 10.94% |
LoseATNM / S&P ATNM unavailable / 4.83% |
LoseATNM / S&P ATNM unavailable / 10.63% |
| 2025-Q11/3 |
WinATNM / S&P 27.78% / -4.27% |
LoseATNM / S&P ATNM unavailable / 4.98% |
LoseATNM / S&P ATNM unavailable / 10.57% |
| 2024-Q40/3 |
LoseATNM / S&P -32.98% / 2.41% |
LoseATNM / S&P ATNM unavailable / 5.25% |
LoseATNM / S&P ATNM unavailable / 6.15% |
| 2024-Q30/3 |
LoseATNM / S&P -74.59% / 5.89% |
LoseATNM / S&P ATNM unavailable / 5.89% |
LoseATNM / S&P ATNM unavailable / 6.11% |
| 2024-Q20/3 |
LoseATNM / S&P -5.49% / 4.28% |
LoseATNM / S&P ATNM unavailable / 5.38% |
LoseATNM / S&P ATNM unavailable / 5.12% |
| 2024-Q11/3 |
WinATNM / S&P 54.13% / 10.56% |
LoseATNM / S&P ATNM unavailable / 5.71% |
LoseATNM / S&P ATNM unavailable / 5.59% |
| 2023-Q40/3 |
LoseATNM / S&P -14.19% / 11.69% |
LoseATNM / S&P -92.14% / 6.81% |
LoseATNM / S&P ATNM unavailable / 7.78% |
| 2023-Q30/3 |
LoseATNM / S&P -20.22% / -3.27% |
LoseATNM / S&P ATNM unavailable / 7.52% |
LoseATNM / S&P ATNM unavailable / -5.03% |
| 2023-Q20/3 |
LoseATNM / S&P -21.48% / 8.74% |
LoseATNM / S&P ATNM unavailable / 9.50% |
LoseATNM / S&P ATNM unavailable / -8.57% |
| 2023-Q10/3 |
LoseATNM / S&P -11.27% / 7.50% |
LoseATNM / S&P ATNM unavailable / 10.77% |
LoseATNM / S&P ATNM unavailable / -15.69% |
| 2022-Q41/3 |
WinATNM / S&P 44.31% / 7.56% |
LoseATNM / S&P -9.97% / 11.88% |
LoseATNM / S&P ATNM unavailable / -17.99% |
| 2022-Q31/3 |
WinATNM / S&P 53.43% / -4.88% |
LoseATNM / S&P ATNM unavailable / 13.47% |
LoseATNM / S&P ATNM unavailable / -1.41% |
| 2022-Q21/3 |
WinATNM / S&P -5.87% / -16.10% |
LoseATNM / S&P ATNM unavailable / 13.71% |
LoseATNM / S&P ATNM unavailable / 11.04% |
| 2022-Q10/3 |
LoseATNM / S&P -14.98% / -4.60% |
LoseATNM / S&P ATNM unavailable / 15.97% |
LoseATNM / S&P ATNM unavailable / 42.23% |
| 2021-Q40/3 |
LoseATNM / S&P -32.17% / 11.03% |
LoseATNM / S&P ATNM unavailable / 15.00% |
LoseATNM / S&P ATNM unavailable / 96.40% |
| 2021-Q31/3 |
WinATNM / S&P 12.01% / 0.58% |
LoseATNM / S&P ATNM unavailable / 10.77% |
LoseATNM / S&P ATNM unavailable / 69.42% |
| 2021-Q20/3 |
LoseATNM / S&P 3.81% / 8.55% |
LoseATNM / S&P ATNM unavailable / 6.58% |
LoseATNM / S&P ATNM unavailable / 51.81% |
| 2021-Q10/3 |
LoseATNM / S&P -2.31% / 6.17% |
LoseATNM / S&P ATNM unavailable / -1.06% |
LoseATNM / S&P ATNM unavailable / 7.39% |
| 2020-Q40/3 |
LoseATNM / S&P -19.50% / 12.15% |
LoseATNM / S&P ATNM unavailable / -3.72% |
LoseATNM / S&P ATNM unavailable / -33.42% |
| 2020-Q30/3 |
LoseATNM / S&P -8.24% / 8.93% |
LoseATNM / S&P ATNM unavailable / -2.04% |
LoseATNM / S&P ATNM unavailable / -27.10% |
| 2020-Q21/3 |
WinATNM / S&P 81.44% / 20.54% |
LoseATNM / S&P ATNM unavailable / -0.46% |
LoseATNM / S&P ATNM unavailable / -27.11% |
| 2020-Q11/3 |
WinATNM / S&P -11.01% / -19.60% |
LoseATNM / S&P ATNM unavailable / 3.47% |
LoseATNM / S&P ATNM unavailable / -14.75% |
| 2019-Q40/3 |
LoseATNM / S&P -5.22% / 9.07% |
LoseATNM / S&P ATNM unavailable / 5.36% |
LoseATNM / S&P ATNM unavailable / 2.99% |
| 2019-Q30/3 |
LoseATNM / S&P -6.50% / 1.70% |
LoseATNM / S&P ATNM unavailable / 5.02% |
LoseATNM / S&P ATNM unavailable / 0.21% |
| 2019-Q20/3 |
LoseATNM / S&P -48.75% / 4.30% |
LoseATNM / S&P ATNM unavailable / 6.64% |
LoseATNM / S&P ATNM unavailable / 8.65% |
| 2019-Q11/3 |
WinATNM / S&P 24.03% / 13.65% |
LoseATNM / S&P ATNM unavailable / 8.12% |
LoseATNM / S&P ATNM unavailable / 14.29% |
| 2018-Q40/3 |
LoseATNM / S&P -47.84% / -13.52% |
LoseATNM / S&P ATNM unavailable / 9.05% |
LoseATNM / S&P ATNM unavailable / 18.23% |
| 2018-Q31/3 |
WinATNM / S&P 15.94% / 7.71% |
LoseATNM / S&P ATNM unavailable / 10.21% |
LoseATNM / S&P ATNM unavailable / 19.06% |
| 2018-Q21/3 |
WinATNM / S&P 75.34% / 3.43% |
LoseATNM / S&P ATNM unavailable / 9.03% |
LoseATNM / S&P ATNM unavailable / 14.46% |
| 2018-Q10/3 |
LoseATNM / S&P -45.03% / -0.76% |
LoseATNM / S&P ATNM unavailable / 7.68% |
LoseATNM / S&P ATNM unavailable / 12.46% |
| 2017-Q41/3 |
WinATNM / S&P 15.48% / 6.64% |
LoseATNM / S&P ATNM unavailable / 7.03% |
LoseATNM / S&P ATNM unavailable / 13.82% |
| 2017-Q30/3 |
LoseATNM / S&P -52.87% / 4.48% |
LoseATNM / S&P ATNM unavailable / 5.68% |
LoseATNM / S&P ATNM unavailable / 17.57% |
| 2017-Q20/3 |
LoseATNM / S&P -19.21% / 3.09% |
LoseATNM / S&P ATNM unavailable / 4.83% |
LoseATNM / S&P ATNM unavailable / 17.74% |
| 2017-Q11/3 |
WinATNM / S&P 72.57% / 6.07% |
LoseATNM / S&P ATNM unavailable / 3.67% |
LoseATNM / S&P ATNM unavailable / 13.32% |
| 2016-Q40/3 |
LoseATNM / S&P -35.19% / 3.82% |
LoseATNM / S&P ATNM unavailable / 2.09% |
LoseATNM / S&P ATNM unavailable / 7.05% |
| 2016-Q30/3 |
LoseATNM / S&P -23.73% / 3.85% |
LoseATNM / S&P ATNM unavailable / 0.20% |
LoseATNM / S&P ATNM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ATNM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -44.62% | 20.78% |
| Annualized return | -44.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ATNM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -83.76% | 83.14% |
| Annualized return | -30.48% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ATNM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.13% | 319.30% |
| Annualized return | -32.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |